Updates and Insights on HER2 in Breast Cancer in Sohag Governorate

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
* To evaluate HER2 expression in breast carcinoma with emphasizing HER2-ultralow, and HER2-low, HER2 equivocal tumors. * To correlate the results of HER2 with clinico-pathological prognostic parameters; examples tumor grade, Ki-67 proliferation index, nodal status, tumor size, lympho-vascular invasion, and perineural invasion, tumor infiltrating lymphocytes * To access interobserval agreement in HER2 score interpretation
Epistemonikos ID: f526545b78074b335f3a7efde879b1ae8cdc8519
First added on: Aug 12, 2026